134 related articles for article (PubMed ID: 3517510)
41. The activation of tumoricidal properties in macrophages of endotoxin responder and nonresponder mice by liposome-encapsulated immunomodulators.
Fogler WE; Talmadge JE; Fidler IJ
J Reticuloendothel Soc; 1983 Mar; 33(3):165-74. PubMed ID: 6834360
[TBL] [Abstract][Full Text] [Related]
42. Defective tumoricidal capacity of macrophages from P/J mice: tumoricidal defect involves abnormalities in lymphokine-derived activation stimuli and in mononuclear phagocyte responsiveness.
Boraschi D; Meltzer MS
J Immunol; 1980 Aug; 125(2):777-82. PubMed ID: 6993563
[No Abstract] [Full Text] [Related]
43. Mechanism of lymphocyte activation. II. Requirements for macromolecular synthesis in the production of lymphokines.
Varesio L; Holden HT; Taramelli D
J Immunol; 1980 Dec; 125(6):2810-7. PubMed ID: 6159423
[TBL] [Abstract][Full Text] [Related]
44. Pertussigen in vivo enhances antigen-specific production in vitro of lymphokine that stimulates macrophage procoagulant activity and plasminogen activator.
de Moerloose PA; Hamilton JA; Sewell WA; Vadas MA; Mackay IR
J Immunol; 1986 Dec; 137(11):3528-33. PubMed ID: 3782790
[TBL] [Abstract][Full Text] [Related]
45. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells.
Yamamoto N; Kumashiro R
J Immunol; 1993 Sep; 151(5):2794-802. PubMed ID: 8360493
[TBL] [Abstract][Full Text] [Related]
46. Defective tumoricidal capacity of macrophages from A/J mice. II. Comparison of the macrophage cytotoxic defect of A/J mice with that of lipid A-unresponsive C3H/HeJ mice.
Boraschi D; Meltzer MS
J Immunol; 1979 Apr; 122(4):1592-97. PubMed ID: 376721
[No Abstract] [Full Text] [Related]
47. Spontaneous T-cell lymphokine production and enhanced macrophage Ia expression and tumoricidal activity in MRL-lpr mice.
Lu CY; Unanue ER
Clin Immunol Immunopathol; 1982 Nov; 25(2):213-22. PubMed ID: 6762274
[No Abstract] [Full Text] [Related]
48. In vitro modulation of macrophage tumoricidal activity: partial characterization of a macrophage-activating factor(s) in supernatants of NaIO4-treated peritoneal cells.
Weinberg JB; Hibbs JB
J Reticuloendothel Soc; 1979 Sep; 26(3):283-93. PubMed ID: 228037
[No Abstract] [Full Text] [Related]
49. Modulation of growth-stimulating and antitumor activity of macrophages by BCG and cyclophosphamide.
Okulov VB; Voytenkov BO; Gromov SA
APMIS Suppl; 1988; 2():130-5. PubMed ID: 3052516
[TBL] [Abstract][Full Text] [Related]
50. [Soluble active substances formed by lymphocytes and macrophages; new trends in lymphokine and monokine research].
Nakano M
Nihon Rinsho; 1983; 41(4):711-7. PubMed ID: 6350644
[No Abstract] [Full Text] [Related]
51. Functional characterization of lymphokines from the EL-4 T cell line that activate macrophages for nonspecific tumor cytotoxicity.
Occhionero M; Leonard EJ; Meltzer MS
J Leukoc Biol; 1984 Apr; 35(4):405-14. PubMed ID: 6368713
[TBL] [Abstract][Full Text] [Related]
52. Identification and characterization of a monoclonal antibody to an antigen expressed on activated macrophages.
Koestler TP; Rieman D; Muirhead K; Greig RG; Poste G
Proc Natl Acad Sci U S A; 1984 Jul; 81(14):4505-9. PubMed ID: 6379646
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of growth of Histoplasma capsulatum by lymphokine-stimulated macrophages.
Wu-Hsieh B; Howard DH
J Immunol; 1984 May; 132(5):2593-7. PubMed ID: 6371138
[TBL] [Abstract][Full Text] [Related]
54. Similarities of murine gamma interferon and the lymphokine that renders macrophages cytotoxic.
Kleinschmidt WJ; Schultz RM
J Interferon Res; 1982; 2(2):291-9. PubMed ID: 6811671
[TBL] [Abstract][Full Text] [Related]
55. Macrophage fusion factor elicited from BGG-sensitized lymphocytes.
Warfel AH; Hadden JW
Am J Pathol; 1978 Dec; 93(3):753-70. PubMed ID: 362945
[TBL] [Abstract][Full Text] [Related]
56. Suppression of lymphokine production: II. Macrophage-dependent inhibition of production of macrophage activating factor.
Varesio L; Holden HT; Taramelli D
Cell Immunol; 1981 Sep; 63(2):279-92. PubMed ID: 6456076
[No Abstract] [Full Text] [Related]
57. Production of C3 as a marker of lymphokine-mediated macrophage activation.
Koestler TP; Kirsh R; Kline T; Rieman D; Greig R; Poste G
Cell Immunol; 1984 Aug; 87(1):1-14. PubMed ID: 6378389
[TBL] [Abstract][Full Text] [Related]
58. Mouse mononuclear cell chemotaxis: description of system.
Boetcher DA; Meltzer MS
J Natl Cancer Inst; 1975 Mar; 54(3):795-9. PubMed ID: 1091744
[TBL] [Abstract][Full Text] [Related]
59. Studies on the mechanism of liver injury by macrophage-mediated cytotoxicity--partial purification of cytotoxic factor detected in the culture supernatant of activated macrophages.
Mizoguchi Y; Tsutsui H; Monna T; Yamamoto S; Morisawa S
Gastroenterol Jpn; 1983 Feb; 18(1):41-6. PubMed ID: 6339309
[TBL] [Abstract][Full Text] [Related]
60. Human non-interferon macrophage activating factor: biological and biochemical characterization.
Lee JC; Badger AM; Johnson WJ
Adv Exp Med Biol; 1988; 239():217-21. PubMed ID: 3264453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
